Literature DB >> 1916094

Endothelins.

G M Rubanyi1, L H Botelho.   

Abstract

The discovery of endothelium-derived relaxing (prostacyclin, EDRF) and contracting factors (EDCF) in the past decade opened up new vistas not only for basic and clinical research, but revolutionized our thinking about regulation and control of the cardiovascular system in health and disease. One of the most exciting developments in recent years was the discovery of a peptidergic EDCF and its isolation and identification as a unique 21-amino-acid peptide, endothelin (ET). This review summarizes the state-of-the-art in some areas of this fast-moving field, including the biosynthesis, tissue-specific expression, and binding of ET isoforms. Recent information about the nature of endothelin-converting enzyme (ECE) and the cloning, sequencing, and expression of ET receptor subtypes will be discussed. Based on current knowledge of the wide variety of biological actions of ETs, working hypotheses are presented about the possible autocrine, paracrine, and humoral actions of ETs and their potential role in modulating cardiovascular functions. In addition, the proposed significance of ETs in human cardiovascular diseases is summarized. In spite of the abundance of studies generated over the past 3 years and the postulated working hypotheses based on these findings, the true significance of ETs in short- and long-term regulation/modulation of tissue function remains to be determined. This will be the task of future investigations, using more sensitive detection methods and selective inhibitors of the biosynthesis and actions of ETs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1916094     DOI: 10.1096/fasebj.5.12.1916094

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  35 in total

Review 1.  Extracellular matrix contraction by fibroblasts: peptide promoters and second messengers.

Authors:  C Guidry
Journal:  Cancer Metastasis Rev       Date:  1992-03       Impact factor: 9.264

Review 2.  Role of endothelin in diabetic vascular complications.

Authors:  H C Lam
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

3.  Kinetic parameters for the generation of endothelins-1,-2 and -3 by human cathepsin E.

Authors:  P S Robinson; W E Lees; J Kay; N D Cook
Journal:  Biochem J       Date:  1992-06-01       Impact factor: 3.857

Review 4.  The vascular endothelin system in hypertension--recent patents and discoveries.

Authors:  Meri M Hynynen; Raouf A Khalil
Journal:  Recent Pat Cardiovasc Drug Discov       Date:  2006-01

5.  Genome of deerpox virus.

Authors:  C L Afonso; G Delhon; E R Tulman; Z Lu; A Zsak; V M Becerra; L Zsak; G F Kutish; D L Rock
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 6.  Modulators of the vascular endothelin receptor in blood pressure regulation and hypertension.

Authors:  Raouf A Khalil
Journal:  Curr Mol Pharmacol       Date:  2011-11       Impact factor: 3.339

7.  Presence of endothelin-1 in the normal and pathological human thyroid.

Authors:  M Lenziardi; P Viacava; I Fiorini; M Castagna; V Nardini; L Pollina; F De Negri; O Goletti; G Di Coscio; G Bevilacqua
Journal:  J Endocrinol Invest       Date:  1995-05       Impact factor: 4.256

8.  Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease.

Authors:  Hong-Qiang Feng; Nate D Weymouth; Don C Rockey
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-03-19       Impact factor: 4.052

9.  RNAi silencing of brain klotho potentiates cold-induced elevation of blood pressure via the endothelin pathway.

Authors:  Xiuqing Wang; Zhongjie Sun
Journal:  Physiol Genomics       Date:  2010-01-19       Impact factor: 3.107

10.  Fluid shear stress differentially modulates expression of genes encoding basic fibroblast growth factor and platelet-derived growth factor B chain in vascular endothelium.

Authors:  A M Malek; G H Gibbons; V J Dzau; S Izumo
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.